GeneTex, Inc. started operations in early 1997 in San Antonio, Texas, and has recently moved to Irvine in California. The company was founded by three internationally known scientists with recognized expertise in oncology and infectious diseases and a businessperson with extensive experience in startup biotechnology companies.
Based on the breadth of experience and expertise of their scientific founders, the companys initial focus was concentrated on a portfolio of reagents that met the needs of researchers working to solve the puzzle of what causes cancer, how cancer can be better diagnosed, and how aggressive a treatment the doctor and patient ought to consider.
Their very first products were directed toward breast cancer research and prognosis. More recently, they have added tools for scientists studying basic mechanisms common to many forms of cancer. These research tools include immunological reagents used to study specific proteins and events involved in the regulation of the cell cycle and DNA repair and replication.
Their range is extensive and includes over 16,000 high quality primary antibodies, DNA/RNA/oligos, cell/tissue lysates, isotype controls, proteins/peptides and research kits.
